Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663387 · ClinicalTrials.gov registry record
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 116
- Enrollment target
NCT03663387 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 116 participants.
The verdict
NCT03663387 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to measure cerebrospinal fluid (CSF) clearance. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Researchers have considered that impaired clearance of amyloid (a protein) from the aging brain causes buildup of amyloid in the brain and plays a role in increased risk for Alzheimer's disease. However, until recently, there has not been a method to measure CSF clearance. This study will examine CSF clearance using positron emission tomography (PET) scanning, which creates images of structures in the body and their functioning. This study will also measure the amount of two proteins, tau and amyloid, in the brain. Tau and amyloid are proteins that build up in the brains of people with Alzheimer's disease. An investigational compound (tracer) called \[18F\]MK-6240 is injected into the blood prior to the scan in order to take images of the CSF clearance and measure tau protein in the brain. This tracer is considered investigational because it is not approved by the US Food and Drug Administration (FDA) for clinical use and is only being used for research purposes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2022-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663387
The ClinicalTrials.gov registry entry for NCT03663387 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03663387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03663387 about?
NCT03663387 is a clinical study titled "PET Measures of CSF Clearance in Preclinical Alzheimer's Disease". The purpose of this study is to measure cerebrospinal fluid (CSF) clearance. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Researchers have considered that impaired clearance of amyloid (a protein) from the aging ...
What is the current status of trial NCT03663387?
This trial is currently completed. The enrollment target is 116 participants. The study started on 2018-07-30. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT03663387?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.